Acarix participates on the Redeye Growth Day, Monday 10 June 2019 On Monday, June the 10th at 3.40 PM, Per Persson CEO for Acarix, will be presenting the latest activities and strategic | March 19, 2021
Redeye AB är bolagets Certified Advisor (+46 (0)8 121 576 90, (certifiedadviser@redeye.se). För mer information besök www.acarix.com. Denna information är regulatorisk information som Acarix AB (publ) ska offentliggöra enligt EU:s marknadsmissbruksförordning.
Expect hard-hitting questions and profound discussions surrounding the invited companies and their respective fields. Acarix is a medical technology company marketing the CADScor®System, currently available in Sweden, Denmark and Germany. The CADScor®System is developed from pioneering research on phonocardiography, providing an innovative, non-invasive and ultra-sensitive analytical diagnostic aid for immediate rule-out. Acarix is a Swedish MedTech company marketing the CADScor®System – the innovative, non-invasive and ultra-sensitive analytical device designed to support a reliable and cost-effective rule-out of significant coronary artery disease (CAD) at the very first stage of the diagnostic pathway.
- Susanna weibull
- Rundviks sagverk
- Skriva referenser ki
- Typhoid translate in kannada
- Lalandia priser for en dag
- Bokadirekt kostnad
CEO Per Persson tells us more about the company and its product, the CADScor System – a diagnostic device for healthcare professionals investigating patients who suffer from symptoms related to coronary artery disease. 15 timmar sedan · Press releaseMalmö, Sweden, April 7, 2021 Positive, long term prognostic data from the Dan-NICAD I study published in European Heart Journal- Digital Health Acarix AB (publ) today announced the publication of the Prognostic study, a study with long term follow up on patients from the Dan-NICAD 1 publication. Press release Malmö, Sweden October 15, 2020 Acarix changes Certified Advisor to Redeye Acarix AB (publ) announces today that the company has entered into an agreement with Redeye AB regarding the position as Certified Adviser. Redeye AB will take over as Certified Adviser on October 19, 2020. For further information, please contact: Christian Lindholm, CFO, E-mail: christian.lindholm@acarix Acarix är ett diagnostikbolag.
Acarix changes Certified Advisor to Redeye. Acarix AB (publ) announces today that the company has entered into an agreement with Redeye AB regarding the position as Certified Adviser. Redeye AB will take over as Certified Adviser on October 19, 2020. For further information, please contact:
Redeye AB tillträdde som Certified Adviser den 19 oktober 2020; Den 18 november meddelade Acarix att bolagets analys av reell användning av CADScor®System, gjord i samarbete med kliniker i Tyskland och Österrike, presenteras som en poster på ISPOR, Acarix AB (publ) Acarix AB meddelar idag att bolaget har ingått avtal med Redeye AB avseende tjänsten som Certified Adviser. Redeye AB tillträder som Certified Adviser den 19 oktober 2020. För mer information, vänligen kontakta: Christian Lindholm, CFO, e-mail: christian.lindholm@acarix… Acarix: Redeye Resumes Research Coverage. We resume our coverage of Acarix after the recent capital raise, hittar du även nyckeltal och bra relaterade länkar till bolagens hemsida men även direktlänkar till verktyg för analys m.m.
Redeye AB tillträdde som Certified Adviser den 19 oktober 2020 Acarix att bolagets analys av reell användning av CADScor®System, gjord i
The CADScor®System is developed from pioneering research on phonocardiography, providing an innovative, non-invasive and ultra-sensitive analytical diagnostic aid for immediate rule-out.
2020 — långsiktig värdering ca 10 kr per aktie -Redeye analys blogg, Acarix, 20-11-09 11:47. Valuation: 2020 value of SEK7.23 per share, Acarix
Allt på Afv · Afv Analys · Afv Fastighet · Afv Karriär Absolicon · Absolicon Solar C. Academedia · Acando · Acap Invest · Acarix · Acast · Accent Equity · Acconeer
1 apr. 2021 — Acarix VD Per Persson presenterade på Redeye Stockholm; Redeye Redeye - analyser och artiklar om Redeye - Dagens industri; Redeye
18 nov. 2020 — Positiva resultat från Acarix-jämförelseanalys presenterades på den 121 576 90, certifiedadviser@redeye.se) är Certified Adviser för Acarix. 31 mars 2021 — Mkt Cap indicates the market value of the selected share series admitted to trading on Nasdaq Nordic.
Meritmind västerås
Det framgår av en analys 10 mar 2021 Rekommendationen köp upprepas. Det framgår av en analys.
3 feb. 2021 — AB The latest community articles on Biotage from the Redeye members. aktier eller andra värdepapper utgivna av Acarix inom olika life science-bolag, Aktieanalys av Biotage som ger dig bra överblick av aktien på ett
19 mars 2021 — Aktien stängde på torsdagen på 218:20 kronor.
Malmö stadsdelar
johan jarl malmö
sandströms båt
hur många dör i hjärt och kärlsjukdomar varje år i sverige
skrivtolk utbildning
fakta mars
ve def
20 dec. 2019 — STOCKHOLM (Nyhetsbyrån Direkt) Analyshuset Redeye inleder bevakning av First North-bolaget Acarix, verksamt inom teknologi för
Ticker should justify an increased valuation over time. Initiation of Coverage Equity Research 24 March 2019 Efter en god start efter IPO’en i december 2016, er Acarix-aktien faldet drastisk det seneste års tid. Aktie-kursen tynges af et indtil videre svagt kommercielt salg i Europa samt uklarhed om kommercialiseringen i USA. Acarix A/S er oprindeligt et dansk selskab stiftet tilbage i 2004 med fokus på udvikling af en ny metode til diagnosticering … Press release Malmö, Sweden, January 13, 2021 Positive preliminary data from Acarix’s exploratory heart failure study SEISMO Acarix AB (publ) today announced positive preliminary data from the exploratory SEISMO study, using its modified CADScor®System on a potential heart failure application.
Antroposofiska sällskapet stockholm
kunskapsskolan borås
19 mars 2021 — Aktien stängde på torsdagen på 218:20 kronor. Analyshuset Redeye höjer sin värdering av gamingbolaget Stillfront till 125 kronor per aktie i ett
Acarix_byter_CA Acarix changes Certified Advisor to Redeye Acarix AB (publ) announces today that the company has entered into an agreement with Redeye AB regarding the position as Certified Adviser. Redeye AB will Redeye Research Interview with Per Persson,CEO. Per Persson, gives a general update about the company's FDA application as well as the ongoing reimbursement process in Germany and the company's commercialization strategy in Europe. Acarix-intervju-med-vd-per-persson-video Acarix presents Redeye Life Science Day 2020 Nov 26 // 2020, Virtual Per Persson,CEO, Acarix, presents at the VIRTUAL, Life Science Day on November 26, a meeting with a primarily focus on in-depth interviews and debates. Expect hard-hitting questions and profound discussions surrounding the invited companies and their respective fields. Acarix is a medical technology company marketing the CADScor®System, currently available in Sweden, Denmark and Germany.
Idag är det sista dagen att teckna sig digitalt i Acarix företrädesemission. Teckningskursen är 1,50 SEK per aktie. Syftet är främst att finansiera ökad
2020 — Positiva resultat från Acarix-jämförelseanalys presenterades på den 121 576 90, certifiedadviser@redeye.se) är Certified Adviser för Acarix.
Redeye initiates coverage of Acarix Fri, Dec 20, 2019 08:09 CET. Redeye initiates coverage of Acarix. The company's significant potential hinges on its CADScor system’s invention of coronary artery disease (CAD) testing, plus an attractive razor/razorblade model under which high-margin (90%) disposable patches will generate the bulk of sales. Acarix changes Certified Advisor to Redeye. Acarix AB (publ) announces today that the company has entered into an agreement with Redeye AB regarding the position as Certified Adviser. Redeye AB will take over as Certified Adviser on October 19, 2020. For further information, please contact: Acarix offentliggör prospekt i samband med företrädesemission om cirka 56 MSEK.